| 1 |
35291312 | Cleavage-defective Topoisomerase I mutants sharply increase G-quadruplex-associated genomic instability. | 2022 Mar 7 |
4 |
| 2 |
35345325 | A Yeast-Based Screening System for Differential Identification of Poisons and Suppressors of Human Topoisomerase I. | 2022 Mar 9 |
1 |
| 3 |
32981006 | The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway. | 2021 Apr |
2 |
| 4 |
33352117 | Lipid-derived electrophiles mediate the effects of chemotherapeutic topoisomerase I poisons. | 2021 Jun 17 |
4 |
| 5 |
34649567 | Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling. | 2021 Oct 14 |
2 |
| 6 |
32504778 | DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. | 2020 Aug 10 |
2 |
| 7 |
31049660 | Abortive activity of Topoisomerase I: a challenge for genome integrity? | 2019 Oct |
3 |
| 8 |
31930190 | Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs. | 2019 |
2 |
| 9 |
30209297 | PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin. | 2018 Sep 12 |
4 |
| 10 |
27416553 | Synthesis and biological evaluation of 6-fluoro-3-phenyl-7-piperazinyl quinolone derivatives as potential topoisomerase I inhibitors. | 2016 Oct 21 |
1 |
| 11 |
27933897 | Tyrosyl-DNA Phosphodiesterase 1 Inhibitors: Usnic Acid Enamines Enhance the Cytotoxic Effect of Camptothecin. | 2016 Nov 23 |
1 |
| 12 |
25963854 | Real-time investigation of human topoisomerase I reaction kinetics using an optical sensor: a fast method for drug screening and determination of active enzyme concentrations. | 2015 Jun 7 |
4 |
| 13 |
21135154 | Paradoxical effects of ethoxidine, a topoisomerase I inhibitor, in the cellular processes leading to angiogenesis on endothelial cells. | 2011 Mar |
1 |
| 14 |
22071521 | Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction. | 2011 Dec 15 |
8 |
| 15 |
19549776 | Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. | 2009 Jul 1 |
2 |
| 16 |
19883083 | 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors. | 2009 Nov 26 |
1 |
| 17 |
16935573 | Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. | 2006 Dec 9 |
2 |
| 18 |
17135786 | A comparative study of protein profiling by proteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostate cancer cells. | 2006 |
1 |
| 19 |
15809721 | Blocking of PI3K/Akt pathway enhances apoptosis induced by SN-38, an active form of CPT-11, in human hepatoma cells. | 2005 May |
1 |
| 20 |
12787881 | Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent. | 2003 Jun 15 |
2 |
| 21 |
11230497 | Irinotecan in the treatment of colorectal cancer: clinical overview. | 2001 Mar 1 |
3 |
| 22 |
10101025 | Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death. | 1999 Apr |
4 |
| 23 |
8922198 | Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. | 1996 Oct |
1 |
| 24 |
20650253 | Involvement of CPP32/Yama-like protease in CPT-11-induced death signal transduction pathway. | 1996 Dec |
2 |